Clinical description and development of a prognostic score for neurofibromatosis type 1 (NF1)-associated GISTs: a retrospective study from the NETSARC.

Date publication

mars 2025

Journal

ESMO open

Auteurs

Membres identifiés du Cancéropôle Est :
Pr BOUCHE Olivier , Dr CHAIGNEAU Loïc , Pr GHIRINGHELLI François , Pr KURTZ Jean-Emmanuel , Pr MANFREDI Sylvain

Tous les auteurs :
Cuvelier C, Brahmi M, Sobhani I, Verret B, Grancher A, Penel N, Toulmonde M, Lahlou W, Dupuis H, Calavas L, Muller M, Watson S, Bruyat D, Poumeaud F, Chaigneau L, Manfredi S, Lecomte T, Bertucci F, Ghiringhelli F, Pracht M, Mourthadhoi F, Monceau-Baroux L, Helyon M, Kurtz JE, Roquin G, Regenet N, Vinches M, Tougeron D, Wolkenstein P, Blay JY, Bouche O, Hautefeuille V

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/40043354

Résumé

Gastrointestinal stromal tumors (GISTs) occur in ∼7% of neurofibromatosis type 1 (NF1) patients. Data about their natural history remain scarce and neither risk classifications, prognosis model nor adjuvant treatment have been validated in this population.

Mots clés

adjuvant treatment, gastrointestinal stromal tumor (GIST), imatinib, mitotic count, neurofibromatosis type 1 (NF1), recurrence-free survival (RFS)

Référence

ESMO Open. 2025 03 4;10(3):104477